KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 62 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q2 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,515,305 | +64.2% | 317,519 | +33.1% | 0.01% | +100.0% |
| Q2 2023 | $3,359,488 | +30.2% | 238,600 | -0.5% | 0.00% | 0.0% |
| Q1 2023 | $2,580,119 | -27.5% | 239,788 | +1.0% | 0.00% | -25.0% |
| Q4 2022 | $3,556,926 | +147.0% | 237,445 | +111.7% | 0.00% | +100.0% |
| Q3 2022 | $1,440,000 | +246.2% | 112,171 | +161.3% | 0.00% | – |
| Q2 2022 | $416,000 | +186.9% | 42,928 | +248.5% | 0.00% | – |
| Q4 2021 | $145,000 | -83.6% | 12,317 | -75.4% | 0.00% | -100.0% |
| Q4 2020 | $885,000 | -43.6% | 50,089 | -51.1% | 0.00% | -50.0% |
| Q3 2020 | $1,569,000 | +24.7% | 102,386 | +107.3% | 0.00% | +100.0% |
| Q2 2020 | $1,258,000 | +255.4% | 49,382 | +89.0% | 0.00% | – |
| Q2 2019 | $354,000 | -79.4% | 26,134 | -72.6% | 0.00% | -100.0% |
| Q1 2019 | $1,720,000 | +541.8% | 95,256 | +898.3% | 0.00% | – |
| Q4 2018 | $268,000 | – | 9,542 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Spearhead Capital Advisors, LLC | 202,580 | $2,601,000 | 2.82% |
| Lion Point Capital, LP | 480,000 | $5,140,000 | 1.13% |
| HHLR ADVISORS, LTD. | 2,920,023 | $37,493,000 | 0.99% |
| TANG CAPITAL MANAGEMENT LLC | 600,000 | $7,704,000 | 0.94% |
| Rubric Capital Management LP | 1,446,107 | $18,568,000 | 0.94% |
| AlphaCentric Advisors LLC | 43,000 | $552,000 | 0.57% |
| RICE HALL JAMES & ASSOCIATES, LLC | 749,933 | $9,629,000 | 0.56% |
| Parkman Healthcare Partners LLC | 126,192 | $1,620,000 | 0.46% |
| Birchview Capital, LP | 30,000 | $385,000 | 0.27% |
| Baker Brothers Advisors | 2,799,577 | $35,947,000 | 0.24% |